Quest Diagnostics (DGX)

DGX stock rises on a new partnership with MD Anderson to develop a blood test targeting multiple cancer risks.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

With women's health increasingly becoming a global priority, investors are actively targeting companies operating in this space to boost their portfolios. Research and Markets projects the women's hea...

DGX has shown notable strength in the past year, driven by robust core performance and contributions from acquisitions.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Quest Diagnostics continues to stay on investors' radars due to its robust Advanced Diagnostics offerings and strength in acquisitions.

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Quest Diagnostics excels in scale, scope, and service quality, leveraging automation and distribution to reduce costs and offer comprehensive test menus. Despite its strengths, I recommend waiting to ...

Quest Diagnostics Incorporated DGX posted better-than-expected first-quarter earnings on Tuesday.